PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 143 products for "PD-1/PD-L1".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Purity:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.14 kDaSintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Purity:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Color and Shape:LiquidMolecular weight:143.78 kDaZimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Purity:95%Color and Shape:Transparent LiquidMolecular weight:146.54 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purity:95.07%Color and Shape:SolidMolecular weight:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purity:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.03 kDaBMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purity:97.36%Color and Shape:SolidMolecular weight:631.11Ref: TM-T10565
1mg52.00€5mg120.00€1mL*10mM (DMSO)169.00€10mg187.00€25mg380.00€50mg612.00€100mg973.00€200mg1,305.00€Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Purity:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.72 kDaDostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purity:>95%Color and Shape:Transparent LiquidMolecular weight:144.18 kDaTislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purity:95.07%Color and Shape:Transparent LiquidMolecular weight:145 kDaEzabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purity:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Color and Shape:LiquidMolecular weight:145.21 kDaSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purity:SDS-PAGE:95.2%;SEC-HPLC:96.3%Color and Shape:LiquidMolecular weight:145.74 kDaAUNP-12
CAS:AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.Formula:C142H226N40O48Purity:98%Color and Shape:SolidMolecular weight:3261.55PD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purity:99.92%Color and Shape:SolidMolecular weight:348.44Ref: TM-T9651
1mg57.00€2mg85.00€5mg127.00€1mL*10mM (DMSO)140.00€10mg178.00€25mg298.00€50mg405.00€100mg535.00€500mg1,063.00€PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Color and Shape:Odour SolidPD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Color and Shape:Odour SolidPD-1/PD-L1-IN-50
Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.Color and Shape:Odour SolidAcrixolimab
CAS:Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].Purity:98%Color and Shape:LiquidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Color and Shape:SolidMolecular weight:2602.69Anti-Mouse PD-L1 Antibody (10F.9G2)
Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.Purity:98.92% - >95.0% (SDS-PAGE); 99.6% (SEC-HPLC)Color and Shape:LiquidMolecular weight:150 kDaOpamtistomig
CAS:Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.Color and Shape:Liquid
